Are we getting closer to a GLP-1 weight loss pill?

A Senate committee has handed down 47 recommendations after an inquiry into the extent, regulation and management of PFAS "forever chemicals".

Also a major journal publishes a series on the issue of ultra-processed foods which have been associated with a range of chronic health conditions. 

And results from a drug company-funded trial looking at a pill version of a GLP-1, as the race to develop oral treatments ramps up. 

References

• PFAS inquiry hands down 47 recommendations to better regulate 'forever chemicals' in Australia - ABC News 
• The Lancet series on ultra-processed foods
• Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial